First Controlled Trial Indicates Superiority of High Frequency SCS for Pain Management

Results from what is described as the first randomized controlled trial comparison indicate the superiority of high frequency (HF10) spinal cord stimulation (SCS) over traditional lower frequency SCS in response rate and degree of pain relief. The findings were reported in a scientific poster at the annual meeting of the American Academy of Pain Medicine. The superior results were also achieved without the paresthesia that may cause discomfort with traditional SCS, according to the authors.

Traditional SCS low frequency (~50 Hz) stimulation is an attempt to mask the sensation of pain with a tingling or buzzing sensation, known as paresthesia, and the therapeutic goal is to cover the areas of pain with paresthesias. The scientific literature indicates that achieving back pain coverage with traditional SCS is technically difficult and is often not sustained over time. By contrast, HF10 therapy employs a much higher stimulation frequency (10 kHz) that does not produce paresthesias. At present, HF10 therapy is investigational in the United States. The manufacturer of the device, Nevro Corp., which funded this study, anticipates obtaining market approval from the FDA by mid-2015.

Read a news story about the study findings here.

View related content here.


Related Content